Fused pyrimidines of formula (I) wherein A represents a thiophene or furan ring n is 1 or 2 R1 is a group of formula (II) wherein m is 0 or 1 R30 is H or C1-C6 alkyl R4 and R5 form, together with the N atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic group which includes 0 or 1 additional heteroatoms selected from N, S and O, which may be fused to a benzene ring and which is unsubstituted or substituted or one of R4 and R5 is alkyl and the other is a 5- or 6-membered saturated N-containing heterocyclic group as defined above or an alkyl group which is substituted by a 5- or 6-membered saturated N-containing heterocyclic group as defined above R2 is selected from formula (a) wherein R6 and R7 form, together with the nitrogen atom to which they are attached, a morpholine, thiomorpholine, piperidine, piperazine, oxazepane or thiazepane group which is unsubstituted or substituted and formula (b) wherein Y is a C2-C4 alkylene chain which contains, between constituent carbon atoms of the chain and/or at one or both ends of the chain, 1 or 2 heteroatoms selected from O, N and S, and which is unsubstituted or substituted and R3 is an indazole group which is unsubstituted or substituted and the pharmaceutically acceptable salt thereof have activity as inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.Cette invention concerne des pyrimidines fusionnées représentées par la formule (I) dans laquelle A désigne un cycle thiophène ou furane n désigne 1 ou 2 R1 désigne un groupe représenté par la formule (II) dans laquelle m désigne 0 ou 1 R30 désigne H ou alkyle C1-C6 R4 et R5 forment, avec latome N auquel ils sont fixés, un groupe hé
